葵花药业：克立硼罗软膏申请注册上市许可获得受理

Core Viewpoint - The company announced that its wholly-owned subsidiary, Harbin Kuaihua Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration regarding the application for the registration and marketing authorization of Clobetasol Propionate Ointment, which is intended for local treatment of mild to moderate atopic dermatitis in patients aged 3 months and older [1] Group 1 - The product is classified as a Class 4 chemical drug [1] - The drug review process is lengthy and involves multiple steps, leading to uncertainty regarding the completion time and approval results [1] - The company will actively promote the marketing authorization process for this product and will continue to monitor the approval status, ensuring timely information disclosure [1]